Background: Anesthetic and ischemic preconditioning share similar signal transduction pathways. The authors tested the hypothesis that the ␤ 1 -adrenergic signal transduction pathway mediates anesthetic and ischemic preconditioning in vivo.
ISCHEMIC and anesthetic preconditioning against myocardial infarction share similar signal transduction pathways, including guanine regulatory protein (G protein)-coupled receptors, protein kinase C, 1 inhibitory G proteins (G i ), 2 and mitochondrial and sarcolemmal adenosine triphosphate-regulated potassium (K ATP ) channels. [3] [4] [5] Stimulation of G protein-coupled receptors, such as adenosine type 1, 6 opioid ␦ 1 , 7 or ␣ 1 -adrenergic receptors, 8 plays a major role in the preconditioning process. The role of the G protein-coupled ␤ 1 -adrenergic receptor (␤ 1 -AR) in the signaling cascade of preconditioning is unclear. The ␤ 1 -AR subtype is coupled to a G s protein, responding to catecholamine stimulation in the myocardium with an increase of intracellular levels of cyclic adenosine monophosphate. The subsequent activation of protein kinase A (PKA) results in phosphorylation of L-type calcium channels, phospholamban, and myofilaments, thereby evoking contractile and relaxant responses in the heart. 9 Persistent stimulation of ␤ 1 -AR results in dilatative cardiomyopathy, heart failure, and increased apoptosis. 10 However, transient stimulation of ␤ 1 -AR induces cardioprotective effects that are similar to ischemic preconditioning. 11, 12 Moreover, the blockade of ␤-adrenergic receptors attenuates ischemic preconditioning, 13, 14 thus indicating a prominent role for ␤ 1 -AR in preconditioning. The goal of the current study was to elucidate the role of the ␤ 1 -adrenergic pathway in anesthetic and ischemic preconditioning. Therefore, the hypothesis was tested that the inhibition of the ␤ 1 -adrenergic signal transduction pathway blocks desflurane preconditioning, sevoflurane preconditioning, and ischemic preconditioning against myocardial infarction in an in vivo model of myocardial infarction in rabbits.
Materials and Methods
All experimental procedures and protocols used in this investigation were reviewed and approved by the Animal Care and Use Committee of the local authorities (Government of Unterfranken, Würzburg, Germany). Furthermore, all procedures conformed to the Guiding Principles in the Care and Use of Animals of the American Physiologic Society and were in accordance with the Guide for the Care and Use of Laboratory Animals. 15 
General Preparation of Animals
Male New Zealand White rabbits were anesthetized with sodium pentobarbital (30 mg/kg intravenous bolus, followed by an infusion of 20 -30 mg · kg Ϫ1 · h
Ϫ1
) via the left marginal auricular vein. Depth of anesthesia was verified by recurrent testing of palpebral reflexes and hind paw withdrawal throughout the experiment. After tracheotomy and tracheal cannulation, animals were artificially ventilated (Cicero ® ; Dräger, Lübeck, Germany) using positive pressure with an air-oxygen mixture (70% air-30% O 2 ). Arterial blood drawn from the auricular artery was analyzed using an ABL 505 blood gas analyzer (Radiometer, Copenhagen, Denmark), and blood gases were maintained within a normal physiologic range by adjusting the respiratory rate or tidal volume. End-tidal concentrations of desflurane and sevoflurane were measured at the tip of the endotracheal tube by an infrared anesthetic analyzer that was calibrated with known standards before and during experimentation. The rabbit minimum alveolar concentrations (MACs) of desflurane and sevoflurane used in the current investigation were 8.9% 16 and 3.7%, 17 respectively. Left ventricular (LV) pressure and the maximum increase of LV pressure (ϩdP/dt max ) were measured with a salinefilled PE-50 polyethylene catheter inserted into the left ventricle via the right carotid artery. Mean arterial pressure was monitored by insertion of a 2.5-French microtipped catheter (Millar Instruments Inc., Houston, TX) via the right femoral artery into the descending aorta. Rectal body temperature was maintained at 38.5°Ϯ 0.5°C by a servo-controlled heating pad (Föhr Instruments, Seeheim, Germany). After a left fourth thoracotomy and pericardiotomy, the left heart was exposed and suspended in a pericardial cradle. A 4-mm ultrasound probe (Transonic ® ; Ithaca, NY) was placed around the pulmonary artery for measurement of cardiac output. A silk ligature (2-0) was placed halfway between the base and the apex of the heart around a prominent branch of the left anterior descending coronary artery to form a snare. By tightening of the snare, a coronary artery occlusion was produced. Reperfusion was instituted by loosening the snare. Each rabbit received 300 U/kg heparin 5 min before coronary artery occlusion for anticoagulation. Coronary artery occlusion was verified by epicardial cyanosis, regional dyskinesia in the ischemic zone, and electrocardiographic changes. Adequate reperfusion was confirmed by epicardial hyperemic response and reversion of electrocardiographic changes. Hemodynamic parameters, body temperature, and electrocardiogram were continuously recorded and analyzed using a personal computer (Hewlett Packard, Palo Alto, CA; 4 gigabyte) and hemodynamic data acquisition and analysis software (Notocord ® hem 3.5; Croissy sur Seine, France). Data were digitized at a sampling rate of 1,000 Hz.
Experimental Protocol
The experimental protocol used in this investigation is illustrated in figure 1 . Baseline systemic hemodynamics were recorded following a 30-min equilibration period after instrumentation and calibration were completed. All rabbits were subjected to 30 min of coronary artery occlusion followed by 3 h of reperfusion. Rabbits were randomly assigned to receive vehicle (0.9% saline [control]), 1.0 MAC desflurane, 1.0 MAC sevoflurane, or the ␤ 1 -selective blocker esmolol (30.0 mg · kg Ϫ1 · h Ϫ1 ) for 30 min, or a single 5-min cycle of ischemic preconditioning. All interventions were completed 30 min before coronary artery occlusion; thus, a memory period of 30 min was allowed in all groups. Esmolol was coadministered in three separate groups with desflurane, sevoflurane, or a single 5-min cycle of ischemic preconditioning. In a second set of experiments, the selective PKA inhibitor H-89 was given alone and in combination with desflurane, sevoflurane, and single-cycle ischemic preconditioning. H-89 (250 g/kg) was administered directly into the left ventricle 5 min before the onset of desflurane, sevoflurane, and ischemic preconditioning.
Measurement of Myocardial Infarct Size
Infarct size and area at risk (AAR) were gravimetrically determined according to standard procedures. 18 Briefly, at the end of each experiment, the coronary artery was reoccluded, and the AAR was determined by infusion of 2 ml patent blue (0.1 g/ml; Sigma-Aldrich, Taufkirchen, Germany). The rabbits were then killed with a lethal dose of pentobarbital, and the heart was rapidly excised. The heart was cut into five slices from apex to base, and the nonstained red myocardium (AAR) was separated from the nonischemic blue-stained LV normal areas. The samples of ischemic and nonischemic regions were incubated at 37°C for 20 min in 1% 2,3,5-triphenyltetrazolium chloride (Sigma-Aldrich, Steinheim, Germany) in 0.1 M phosphate buffer adjusted to pH 7.4. After overnight storage in 10% formaldehyde, infarcted (pale) and noninfarcted (brick-red) myocardium within the AAR were carefully separated and weighed. Infarct size was expressed as a percentage of the AAR. Rabbits with an AAR less than 10% of LV mass and those with intractable ventricular fibrillation or LV pump failure were excluded from the study.
Determination of ␤ Receptor Selectivity of Esmolol
The ␤ 1 selectivity of esmolol was determined in radioligand binding experiments as described before. I-CYP for ␤ 3 receptors. The incubation buffer contained routinely 100 M GTP. Membranes were incubated for 90 min at 30°C, filtered through Whatman GF/C filters, and washed three times with ice-cold assay buffer. Samples were counted in a ␥-counter (Wallac 1480 Wizard 3"). The K i values of esmolol were calculated by nonlinear curve fitting with the program SCT-FIT 20 and are expressed as geometric means with 95% confidence intervals.
Statistical Analysis
Statistical analysis of data within and between groups was performed with one-way and two-way analysis of variance followed by post hoc Duncan test. Changes were considered statistically significant when the P value was less than 0.05. All data are expressed as mean Ϯ SEM.
Results
Ninety-six rabbits were instrumented to obtain 82 successful experiments. Six rabbits were excluded because of intractable ventricular fibrillation during the experimental protocol (2 control, 1 desflurane, 1 sevoflurane plus esmolol, and 2 desflurane plus H-89), 6 were excluded because of left ventricular pump failure (1 desflurane, 1 desflurane plus esmolol, 1 sevoflurane plus esmolol, 1 H-89, and 2 desflurane plus H-89), and 2 were excluded because LV AAR was less than 10% of the LV mass (1 desflurane plus esmolol and 1 desflurane plus H-89).
Hemodynamics
There were no differences in hemodynamics under baseline conditions between the experimental groups receiving vehicle, desflurane, sevoflurane, esmolol alone or in combination (table 1). Ischemic preconditioning had no effect on systemic hemodynamic variables, whereas desflurane and sevoflurane significantly reduced mean arterial pressure, rate-pressure product, and ϩdP/dtmax during administration. Esmolol alone or in combination with ischemic preconditioning, desflurane, or sevoflurane significantly reduced heart rate and rate-pressure product. Mean arterial pressure and ϩdP/ dtmax were decreased by coadministration of esmolol and desflurane or sevoflurane. Cardiac output and left ventricular end-diastolic pressure were not significantly different throughout the study protocol among all experimental groups. All hemodynamic parameters returned to baseline values before coronary artery occlusion in all experimental groups. During reperfusion, mean arterial pressure and rate-pressure product were reduced similarly in all groups. In the experimental groups receiving H-89, there were no significant differences from the Base ϭ baseline values; CAO ϭ coronary artery occlusion; CON ϭ control; DES ϭ desflurane; DES-ESMO ϭ desflurane plus esmolol; ϩdP/dt max ϭ maximal rate of increase of left ventricular pressure; ESMO ϭ esmolol; HR ϭ heart rate; IPC ϭ ischemic preconditioning; IPC-ESMO ϭ ischemic preconditioning plus esmolol; LVEDP ϭ left ventricular end-diastolic pressure; MAP ϭ mean aortic blood pressure; Mem ϭ memory phase without intervention; Precon ϭ administration of 0.0 or 1.0 minimum alveolar concentration desflurane and sevoflurane or ischemic preconditioning in the presence or absence of esmolol; RPP ϭ rate-pressure product; SEVO ϭ sevoflurane; SEVO-ESMO ϭ sevoflurane plus esmolol.
corresponding groups not receiving H-89 (data not shown).

Myocardial Infarct Size
The LV AAR was similar between groups (table 2) . Myocardial infarct size expressed as a percentage of the AAR was 61 Ϯ 4% (n ϭ 8) in control. Desflurane, sevoflurane, and ischemic preconditioning significantly reduced infarct size to 34 Ϯ 2% (n ϭ 8), 36 Ϯ 5% (n ϭ 8), and 23 Ϯ 3% (n ϭ 8) of the AAR, respectively ( fig. 2 ). Esmolol (n ϭ 8) alone did not alter myocardial infarct size (65 Ϯ 5%) but abolished the protective effects of desflurane and sevoflurane (57 Ϯ 4%, n ϭ 8 and 52 Ϯ 4%, n ϭ 7, respectively). Esmolol significantly attenuated ischemic preconditioning to 40 Ϯ 4% (n ϭ 8). In this group, myocardial infarct size was still significantly smaller than control but significantly larger than ischemic preconditioning alone. The specific PKA inhibitor H-89 alone did not alter infarct size (60 Ϯ 4%, n ϭ 4) but completely abolished desflurane-induced (57 Ϯ 5%, n ϭ 5) and sevoflurane-induced preconditioning (61 Ϯ 1%, n ϭ 5), whereas single-cycle ischemic preconditioning (24 Ϯ 7%, n ϭ 5) was not affected (fig. 3 ).
␤ 1 Selectivity of Esmolol
The binding affinities for esmolol at ␤-AR subtypes were determined in competition binding experiments using membranes from Chinese hamster ovary cells stably transfected with the human subtypes. The respective K i values for ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs are 100 (79 -127), 2,700 (2,050 -3,560), and 4,830 (1,150 -20,300) .
Discussion
In the current study, the volatile anesthetics desflurane and sevoflurane or a single cycle of ischemic preconditioning all markedly reduced infarct size in the rabbit heart in vivo. These results confirm previous studies demonstrating preconditioning against myocardial infarction induced by enflurane, 21 halothane, 21, 22 and isoflurane, [21] [22] [23] [24] and the now widely used volatile anesthetics desflurane 22 and sevoflurane. 25 In the current study, the degree of infarct size reduction did not differ between desflurane and sevoflurane, whereas the study by Piriou et al. 22 using the same model did not demonstrate significant infarct size reduction by sevofluraneinduced preconditioning. These conflicting results might be explained by important differences in study protocols. In the study by Piriou et al., rabbits were anesthetized with ketamine, whereas in our study, sodium pentobarbital was used. Sodium pentobarbital is known to have a negligible effect on preconditioning, 26 whereas ketamine inhibits sarcolemmal and mitochondrial K ATP channels, thereby attenuating anesthetic and ischemic preconditioning. [27] [28] [29] Furthermore, a memory Data are mean Ϯ SEM.
* Significantly (P Ͻ 0.05) different from the respective value in control experiments.
AAR ϭ area at risk; CON ϭ control; DES ϭ desflurane; DES-ESMO ϭ desflurane plus esmolol; ESMO ϭ esmolol; IPC ϭ ischemic preconditioning; IPC-ESMO ϭ ischemic preconditioning plus esmolol; LV ϭ left ventricle; SEVO ϭ sevoflurane; SEVO-ESMO ϭ sevoflurane plus esmolol. period of only 15 min was instituted, in contrast to 30 min in the current study. The degree of infarct size reduction by ischemic and anesthetic preconditioning in our study is in accord with previous findings. 30 To demonstrate the effect of ␤ 1 -AR blockade on preconditioning, the duration of action of the corresponding ␤ blocker must be extremely short. Otherwise, the ␤ blocker will act throughout the ischemia and reperfusion period and thereby might confound ischemiareperfusion injury. In this study, esmolol was chosen over other ␤ 1 -selective drugs because of its extremely short duration of action. Thereby, any effects of ␤ 1 -AR blockade on the ischemia and reperfusion injury could be precluded, and ␤ 1 -AR blockade was maintained only during the preconditioning period. Desflurane-and sevoflurane-induced preconditioning was abolished by concomitant administration of esmolol. In contrast, ischemic preconditioning was significantly attenuated but not completely blocked by the administration of esmolol. Furthermore, the selective PKA inhibitor H-89 completely abolished anesthetic preconditioning by desflurane and by sevoflurane but had no effect on ischemic preconditioning. Both blockers given alone had no effect on myocardial infarct size. Therefore, our findings indicate important differences in the mechanisms of anesthetic and ischemic preconditioning against myocardial infarction in an in vivo model. The involvement of the ␤ adrenergic signal transduction pathway in preconditioning is evidenced by the finding that pharmacologic stimulation of ␤-AR induces preconditioning. In isolated rat hearts, a short 2-min perfusion with noradrenaline or isoproterenol, followed by a 10-min washout period, increased functional recovery of the myocardium. 31 In addition, creatine kinase release was reduced in the groups pretreated with noradrenaline or isoproterenol. These beneficial effects were abolished by the coadministration of the nonselective ␤ blocker timolol. By using selective ␤ blockers, ␤-adrenergic preconditioning was shown to be mainly mediated by the ␤ 1 -AR subtype. 11 In addition, xamoterol, a selective agonist at ␤ 1 -AR, induces protection against ischemia-reperfusion injury in the isolated catecholamine-depleted rat heart. 32 Participation of ␤-AR in ischemic preconditioning has been demonstrated in studies in isolated rabbit 13 and rat hearts.
14 Infarct size reduction, induced by two 5-min cycles of ischemic preconditioning, is attenuated by pretreatment with the ␤ blocker esmolol. 13 Likewise, coadministration of the nonselective ␤ blockers propranolol and nipradilol abolishes cardioprotection induced by a single 3-min cycle of ischemic preconditioning in isolated rat hearts. 14 In the current study, esmolol attenuated cardioprotection induced by a 5-min single cycle of ischemic preconditioning. Therefore, our results confirm and extend these findings into the in vivo animal model. Downstream of the ␤ 1 -AR, the PKA inhibitor H-89 had no effect on ischemic preconditioning.
Volatile anesthetic preconditioning was studied in vitro in the investigation by Hanouz et al. 33 Human right atrial trabeculae were subjected to 30 min of simulated ischemia, and isometric contractile force was measured. Desflurane preconditioning increased functional recovery, and this beneficial effect was abrogated by propranolol. 33 In contrast, in a cellular model of simulated ischemia in isolated rat ventricular cardiomyocytes, propranolol did not affect protection by isoflurane and sevoflurane. 34 In the current in vivo study, esmolol and H-89 abolished desflurane-and sevoflurane-induced preconditioning, thus providing evidence for the role of ␤ 1 -AR signaling in anesthetic preconditioning. It has been suggested that ␤ 1 -ARs exclusively couple to G s proteins. 35, 36 However, a recent study demonstrated that activation of protein kinase C promotes functional coupling of ␤ 1 -ARs to G i proteins. 37 Moreover, activation of PKA leads to phosphorylation of agonist-occupied ␤ 2 -ARs, resulting in an altered coupling specificity of the receptor from G s to G i . 38 Activation of G i proteins results in protein kinase C activation, promoting opening of mitochondrial K ATP channels, 39 which play a central role in volatile anesthetic preconditioning. [3] [4] [5] As an intriguing possibility, anesthetic preconditioning might promote the coupling of ␤ 1 -ARs toward G i coupling. The results of the current investigation, however, demonstrate that G s -coupled downstream signaling plays an important role in anesthetic preconditioning, because inhibition of PKA, the downstream mediator of G s signaling, abrogated anesthetic preconditioning, whereas ischemic preconditioning was not affected. Mechanistically, this might involve altered receptor coupling of ␤ 1 -AR in ischemic preconditioning, a hypothesis that needs further investigation to be proven.
There are several potential limitations to the study that must be considered in the interpretation of the results. The LV AAR for myocardial infarction and coronary collateral blood flow are important determinants of the myocardial infarct size. However, the AAR was not different among experimental groups. Coronary collateral blood flow was not determined in this study. However, coronary collateral blood flow is negligible in rabbits. 40 Systemic hemodynamic changes were introduced by the administration of the volatile anesthetics and esmolol. However, all hemodynamic changes that might have influenced oxygen demand returned to baseline values before coronary occlusion was established. Therefore, it is highly unlikely that hemodynamic changes may have influenced myocardial infarct size. Nevertheless, coronary venous oxygen content was not measured, and myocardial oxygen consumption was not directly quantified in this investigation; therefore, alterations in myocardial oxygen metabolism during and after administration of desflurane, sevoflurane, and esmolol cannot be completely excluded as factors involved in the reduction of infarct size. In this study, the selectivity of esmolol at ␤-AR subtypes was studied in vitro. Our study confirms previous results, indicating that the selectivity of esmolol to ␤ 1 -AR is sufficient and equals that of other ␤ 1 -AR selective agents such as atenolol. 41 However, effects by concomitant blockade of ␤ 2 -or ␤ 3 -AR subtypes cannot completely be excluded. In addition to its action on ␤-AR, esmolol has non-receptor-mediated effects that reduce action potential duration and plateau voltage. 42 It cannot be excluded that these non-receptor-mediated effects influenced infarct size. The PKA inhibitor H-89, although considered selective to PKA, also blocks several other protein kinases, including MSK1, S6K1, ROCK-II, 43 and protein kinase G 44 and directly inhibits K ATP channels in rabbit coronary artery smooth muscle cells. 45 However, K ATP channels play a major role in anesthetic and ischemic preconditioning, and ischemic preconditioning was not affected by H-89. Therefore, it is highly unlikely that K ATP channel inhibition is responsible for the observed effects of H-89 on anesthetic preconditioning. However, these additional effects of H-89 should be borne in mind when interpreting the current findings.
In summary, the results of the current study demonstrate that ␤ 1 -adrenergic signaling plays an important role in anesthetic preconditioning. The results also indicate that activation of the ␤ 1 -adrenergic pathway is not essential for ischemic preconditioning. Therefore, the results suggest important differences in signaling cascades of anesthetic and ischemic preconditioning.
